Back to Newsroom

Sunshine Heart Provides Update on Fully Implantable Circulatory Support System

EDEN PRAIRIE, Minn., July 30, 2015 (GLOBE NEWSWIRE) — Sunshine Heart (NASDAQ:SSH) announced today an update on its next generation, fully implantable version of the Company’s flagship C-Pulse® technology. Sunshine Heart is pleased to report that it will commence a first-in-human study using the novel transcutaneous energy transmission (TET) system and a new smaller implantable pump in Q3 2016.

The study will initially enroll patients at hospitals outside the U.S., and will target patients suffering from advanced Class III/IV heart failure, similar to the patient population of Sunshine Heart’s current ongoing COUNTER HF™ Study. Feasibility of implant, safety and short term durability will be the primary objectives. Performance and efficacy data will be collected to evaluate patient quality of life, freedom from heart failure symptoms and other standard heart failure measures including the ability to bridge to other therapies.

Click here to read more